Corrigendum to ‟Repurposing FDA-approved drugs to fight COVID-19 using in silico methods: Targeting SARS-CoV-2 RdRp enzyme and host cell receptors (ACE2, CD147) through virtual screening and molecular dynamic simulationsˮ [Inform. Med. Unlocked 23 (2021) 1-9/100541].
Journal
Informatics in medicine unlocked
ISSN: 2352-9148
Titre abrégé: Inform Med Unlocked
Pays: England
ID NLM: 101718051
Informations de publication
Date de publication:
04 May 2023
04 May 2023
Historique:
medline:
26
6
2023
pubmed:
26
6
2023
entrez:
26
6
2023
Statut:
aheadofprint
Résumé
[This corrects the article DOI: 10.1016/j.imu.2021.100541.].
Identifiants
pubmed: 37362152
doi: 10.1016/j.imu.2023.101263
pii: S2352-9148(23)00107-7
pmc: PMC10158040
doi:
Types de publication
Published Erratum
Langues
eng
Pagination
101263Commentaires et corrections
Type : ErratumFor
Informations de copyright
© 2023 The Author(s).